AASLD 2024: Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models November 17, 2024 View
SITC 2024: Phase 1, First-in-Human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors November 8, 2024 View
SITC 2024: Pre-clinical efficacy of a novel anti-GPC3 in vivo CAR-M for hepatocellular carcinoma November 8, 2024 View
ASCO 2024: A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors June 1, 2024 View
ASGCT 2024: Genetically Engineered Macrophage Cell Therapy Reverses Liver and Lung Fibrosis in Preclinical Models May 8, 2024 View
ASGCT 2024: Redirected Soluble Modulators (RSM) – A Novel Engineering Strategy to Enhance Immune Receptor Signaling May 8, 2024 View
AACR 2024 POSTER: MACROPHAGES EXPRESSING SYNTHETIC CYTOKINE RECEPTORS REVERSE IL10-MEDIATED IMMUNOSUPPRESSION WITHIN SOLID TUMORS AND PROMOTE ADAPTIVE IMMUNITY April 10, 2024 View
SITC 2023 Poster: A Phase 1, First-in-Human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors. November 3, 2023 View
SITC 2023 Poster: Macrophages expressing synthetic cytokine receptors reverse immunosuppressive signals in solid tumors November 3, 2023 View
SITC 2023 Poster: CAR-Macrophages with custom intronic shRNA exhibit enhanced efficacy against solid tumors November 3, 2023 View
SITC 2023 Poster: In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy November 3, 2023 View
SITC 2023 Oral Abstract: In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy November 3, 2023 View
AACR 2023 Poster: A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119 April 21, 2023 View
AACR 2023 Poster: Macrophages Engineered with Cytokine Switch Receptors: Development of a Modular Platform for Rebalancing Inflammation in Microenvironments April 21, 2023 View
AACR 2023 Poster: A Phase 1, First-in-Human (FIH) Study of Autologous Anti-HER2 Containing an Anti-HER2 Chimeric Antigen Receptor Macrophage (CAR-M) in Participants (pt) with HER2 Overexpressing Solid Tumors April 21, 2023 View
AACR 2022 Poster: Pre-clinical development of CAR Monocytes (CAR Mono) for solid tumor immunotherapy July 14, 2022 View
AACR 2022 Poster: Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy July 14, 2022 View
ASCO 2022 Poster: A Phase 1, First-In-Human (FIH) Study of the Anti-HER2 CAR Macrophage CT-0508 in Participants with HER2 Overexpressing Solid Tumors July 14, 2022 View
SITC 2021 Poster: Development and Characterization of Chimeric Antigen Receptor Monocytes (CAR Mono), a Novel Cell Therapy Platform for Solid Tumor Immunotherapy November 30, 2021 View
SITC 2021 Poster: SIRP⍺-Deficient CAR-Macrophages Exhibit Enhanced Anti-Tumor Function and Bypass the CD47 Immune Checkpoint November 30, 2021 View
SITC 2021 Poster: Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD-1 blockade in immunocompetent mouse models of HER2+ solid tumors November 30, 2021 View
SITC 2021 Poster: LBA (951): A Phase 1 first in human study of adenovirally transduced anti-HER2 CAR Macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data November 30, 2021 View
AACR 2021: Chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models April 9, 2021 View
AACR 2021 Poster: Chimeric antigen receptor macrophages (CAR-M) induce antitumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models April 9, 2021 View
SITC 2020 Poster: Chimeric antigen receptor macrophages (CAR-M) elicit a systemic anti-tumor immune response and synergize with PD-1 blockade in immunocompetent mouse models of HER2+ solid tumors November 10, 2020 View
SITC 2020 Poster: Development of an M1-Polarized, Non-Viral CARMacrophage (CAR-M) Platform for Cancer Immunotherapy November 10, 2020 View
